Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
HT

WKN: A42B0G | ISIN: US4234941031 | Ticker:
NASDAQ
18.11.26 | 21:59
39,180 US-Dollar
+0,08 % +0,030
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HEMAB THERAPEUTICS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
HEMAB THERAPEUTICS HOLDINGS INC 5-Tage-Chart

Aktuelle News zur HEMAB THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
DiHemab Therapeutics treibt drei klinische Programme voran - Solide Liquidität bis 2029-
10.11.Hemab Therapeutics Holdings, Inc. - 10-Q, Quarterly Report-
10.11.Hemab expects cash to fund operations into 2029 while advancing ~75-patient SOLARA Phase III1
10.11.Hemab Therapeutics Holdings Q3 2026 Earnings Call Transcript1
10.11.Hemab Therapeutics Holdings GAAP EPS of -$0.58 misses by $0.061
HEMAB THERAPEUTICS Aktie jetzt für 0€ handeln
10.11.Hemab Therapeutics Holdings, Inc. - 8-K, Current Report-
09.11.Hemab Therapeutics startet Phase-3-Studie für Wirkstoff gegen seltene Blutgerinnungsstörung2
09.11.Hemab Therapeutics, Inc.: Hemab Therapeutics Initiates SOLARA, a Pivotal Phase 3 Trial of Sutacimig in Glanzmann Thrombasthenia1
04.11.Hemab Therapeutics, Inc.: Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition6
15.10.JPMorgan initiates Hemab Therapeutics stock with overweight rating2
12.10.Rodman & Renshaw startet Coverage für Hemab mit Kaufempfehlung - Therapiepotenzial überzeugt3
12.10.Rodman & Renshaw initiates Hemab stock with buy on therapy potential1
24.09.Hemab Therapeutics appoints Keli Walbert to board of directors1
24.09.Hemab Therapeutics, Inc.: Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert295CAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment...
► Artikel lesen
24.09.Hemab Therapeutics Holdings, Inc. - 8-K, Current Report1
17.09.Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding612Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy...
► Artikel lesen
17.09.Hemab Therapeutics, Inc.: Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding412Heavy menstrual bleeding is reported in approximately 1 in 3 reproductive-aged women, according to the American College of Obstetricians and Gynecologists, with approximately 23 million seeking care...
► Artikel lesen
14.08.Biotech Stocks At 52-Week Highs - Park Dental Partners +10%, Aveanna Healthcare +24%, Candel Therapeutics +10% on Q2 Reports, Labcorp Holdings, Hemab Therapeutics1.571LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park...
► Artikel lesen
12.08.H.C. Wainwright hebt Kursziel für Hemab Therapeutics auf 60 US-Dollar an2
11.08.Hemab Therapeutics Holdings, Inc. - 8-K, Current Report1
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1